Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 683 participants.

Also called NCT01896232

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 683 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01896232
  • EudraCT 2013-000192-33
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Canada, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, New Zealand, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01896232. Randomized; double masking; primary purpose treatment. Start 2013-08-13 (actual); primary completion 2014-11-12 (actual). Results posted on 2017-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
Condition
Secondary Hyperparathyroidism
Intervention (Drug)
Etelcalcetide
Intervention (Drug)
Cinacalcet
Intervention (Drug)
Oral Placebo
Intervention (Drug)
Intravenous Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01896232
Content hash
41707a8a700490b4b25da6e96838a44e2f2042afba9502ce62e5c24e72e10678